191 related articles for article (PubMed ID: 28699177)
21. Association of Long-Term Dynamics in Circulating Testosterone with Serum PSA in Prostate Cancer-Free Men with Initial-PSA < 4 ng/mL.
Wang K; Chen X; Cheng TD; Qiu P; Bird VY; Prosperi M
Horm Cancer; 2019 Dec; 10(4-6):168-176. PubMed ID: 31621000
[TBL] [Abstract][Full Text] [Related]
22. Association between prostate cancer and serum testosterone levels.
Zhang PL; Rosen S; Veeramachaneni R; Kao J; DeWolf WC; Bubley G
Prostate; 2002 Nov; 53(3):179-82. PubMed ID: 12386917
[TBL] [Abstract][Full Text] [Related]
23. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
24. Is testosterone treatment good for the prostate? Study of safety during long-term treatment.
Feneley MR; Carruthers M
J Sex Med; 2012 Aug; 9(8):2138-49. PubMed ID: 22672563
[TBL] [Abstract][Full Text] [Related]
25. Significance of focal proliferative atrophy lesions in prostate biopsy cores that test negative for prostate carcinoma.
Asimakopoulos AD; Miano R; Mauriello A; Costantini S; Pasqualetti P; Liberati E; Finazzi Agrò E; Germani S; Virgili G; Vespasiani G
Urol Oncol; 2011; 29(6):690-7. PubMed ID: 20451420
[TBL] [Abstract][Full Text] [Related]
26. Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer.
Bryant AK; McKay RR; Kader AK; Parsons JK; Einck JP; Kane CJ; Mundt AJ; Murphy JD; Rose BS
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1068-1076. PubMed ID: 30543857
[TBL] [Abstract][Full Text] [Related]
27. The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
Porcaro AB; Caruso B; Terrin A; De Luyk N; Cacciamani G; Corsi P; Inverardi D; De Marchi D; Baldassarre R; Cerruto M; Ghimenton C; Brunelli M; Zecchini Antoniolli S; Petrozziello A; Artibani W
Arch Ital Urol Androl; 2016 Mar; 88(1):17-22. PubMed ID: 27072171
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of prostate specific antigen in a European HIV-positive cohort: does one size fit all?
Shepherd L; Borges ÁH; Ravn L; Harvey R; Bower M; Grulich A; Silverberg M; Kronborg G; Galli M; Kirk O; Lundgren J; Mocroft A;
Antivir Ther; 2016; 21(6):529-534. PubMed ID: 26823399
[TBL] [Abstract][Full Text] [Related]
29. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
[TBL] [Abstract][Full Text] [Related]
30. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.
Shiota M; Takeuchi A; Sugimoto M; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Nov; 35(11):6137-45. PubMed ID: 26504040
[TBL] [Abstract][Full Text] [Related]
31. Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.
Fowke JH; Howard L; Andriole GL; Freedland SJ
Eur Urol; 2014 Dec; 66(6):1133-8. PubMed ID: 24568894
[TBL] [Abstract][Full Text] [Related]
32. Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.
Schenk JM; Till C; Hsing AW; Stanczyk FZ; Gong Z; Neuhouser ML; Reichardt JK; Hoque AM; Figg WD; Goodman PJ; Tangen CM; Thompson IM
Cancer Causes Control; 2016 Feb; 27(2):175-82. PubMed ID: 26589415
[TBL] [Abstract][Full Text] [Related]
33. Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy.
Porcaro AB; Tafuri A; Sebben M; Corsi P; Pocessali T; Pirozzi M; Amigoni N; Rizzetto R; Mariotto A; Inverardi D; Brunelli M; Iacovelli R; Romano M; Siracusano S; Artibani W
Urol Int; 2018; 101(1):38-46. PubMed ID: 29975957
[TBL] [Abstract][Full Text] [Related]
34. Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.
Ploussard G; Nicolaiew N; Marchand C; Terry S; Allory Y; Vacherot F; Abbou CC; Salomon L; de la Taille A
BJU Int; 2013 May; 111(6):988-96. PubMed ID: 23452046
[TBL] [Abstract][Full Text] [Related]
35. The role of the serum testosterone levels as a predictor of prostate cancer in patients with atypical small acinar proliferation at the first prostate biopsy.
Dell'Atti L; Galosi AB
Asian J Androl; 2018; 20(1):15-18. PubMed ID: 28695864
[TBL] [Abstract][Full Text] [Related]
36. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
Morote J; Ramirez C; Gómez E; Planas J; Raventós CX; de Torres IM; Catalán R
BJU Int; 2009 Aug; 104(4):486-9. PubMed ID: 19220251
[TBL] [Abstract][Full Text] [Related]
37. Pre- and post-radical prostatectomy testosterone levels in prostate cancer patients.
Lumbiganon S; Patcharatrakul S; Khongcharoensombat W; Sangkum P
Int J Impot Res; 2019 Mar; 31(2):145-149. PubMed ID: 30659293
[TBL] [Abstract][Full Text] [Related]
38. Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection.
Porcaro AB; Tafuri A; Panunzio A; Mazzucato G; Cerrato C; Gallina S; Bianchi A; Rizzetto R; Amigoni N; Serafin E; Cianflone F; Orlando R; Gentile I; Migliorini F; Zecchini Antoniolli S; Di Filippo G; Brunelli M; Pagliarulo V; Cerruto MA; Antonelli A
Int Urol Nephrol; 2022 Mar; 54(3):541-550. PubMed ID: 35044553
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
40. Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial).
Meunier ME; Neuzillet Y; Raynaud JP; Radulescu C; Ghoneim T; Fiet J; Giton F; Rouanne M; Dreyfus JF; Lebret T; Botto H
Prostate; 2019 Feb; 79(3):272-280. PubMed ID: 30370569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]